Parents of kids who struggle with attention know the medication question well: when to raise it, whether to pursue it, and what comes after. A federal enforcement wave is now reshaping that question at the industry level—and what is replacing the old model looks more like what the science always recommended.
Major telehealth ADHD providers are pivoting toward therapy, coaching, and AI-supported care following federal prosecution and conviction of competitors for inappropriate stimulant distribution, Behavioral Health Business reported July 9. The shift is driven by regulatory pressure and by market reality: the prescription-first model is no longer sustainable, legally or clinically.
The surprise for parents is not the crackdown. It is that the industry is finally being pushed toward what decades of evidence backed all along.
Federal enforcement is reshaping the telehealth ADHD industry. Here is what parents need to know about what is changing, what the evidence says, and what to ask next.
Common questions
Should I stop my child’s ADHD medication because of these changes?
What does ADHD coaching actually do for a child?
What questions should I ask my child’s ADHD provider?
My child shows attention difficulties. How do I know where to start?
Telehealth ADHD clinics are pivoting to coaching and therapy now that the prescription-first model ran into federal prosecution. The evidence for skill-based ADHD care was there for decades. The enforcement wave is making it the business model.
What Is Changing, and Why Now
Agave Health and Shimmer are among the telehealth ADHD platforms adding behavioral coaching, therapy, and AI-supported care pathways alongside or in place of their previous medication-management focus. The shift follows a sustained period of federal enforcement that has restructured incentives across the telehealth ADHD space.
In 2024, Cerebral agreed to pay the U.S. government $3.6 million in a non-prosecution agreement over its prescribing practices. In November 2025, Done Global’s CEO and top physician were convicted for inappropriate stimulant distribution and face up to 20 years in prison. The DEA and HHS have extended telemedicine prescribing flexibilities through December 2026 for a fourth time, but the permanent regulatory framework under development would impose stricter requirements on providers who prescribe controlled substances via telehealth without a prior in-person visit.
A parallel data point sharpens the picture. An FDA-commissioned rapid review published in the Journal of Clinical Psychopharmacology in June 2026 found that ADHD stimulant misuse among adults under 30 fell from 7.5 percent in 2016 to 3.7 percent in 2023—a decline researchers partly attribute to the 2022 nationwide Adderall shortage. That 50 percent drop is not a story about behavioral change. It is a story about supply. When prescriptions became harder to obtain, misuse fell by half.
The Evidence Was Never Hard to Find
Coverage of the telehealth ADHD crackdown frames it as a story about abuse prevention and corporate cleanup. That framing is accurate as far as it goes. What it misses is the clinical question sitting inside the enforcement story: the prescription-first model was never what the evidence actually called for.
Evidence-based ADHD treatment guidelines have recommended behavioral intervention alongside medication for decades. CBT has the strongest evidence base among non-medication approaches. Organizational skills training and daily report cards consistently produce the strongest real-world executive function improvements in structured reviews. Multiple meta-analyses confirm that exercise at moderate intensity at least twice weekly over 12-week periods measurably improves working memory, inhibition, and cognitive flexibility in children with ADHD. These are not fringe alternatives. They are first-line recommendations that a 15-minute intake and an auto-refill platform had no structural room to deliver.
The gap matters because ADHD is not one thing. Attention, working memory, executive function, and processing speed are distinct cognitive systems, and a prescription that smooths dopamine signaling does not build the executive function pathways that practice builds. Special education’s own research documents what happens when a support is handed out because it is easier than addressing the actual gap: the incentive to build the underlying skill disappears, and dependence sets in. A telehealth model that starts and ends with a prescription was always delivering half the answer.
Key takeaways
- Telehealth ADHD providers are adding coaching and therapy under regulatory pressure: Agave Health and Shimmer are expanding beyond medication management following federal conviction of competitors for inappropriate stimulant distribution and a restructuring of telehealth prescribing rules.
- ADHD stimulant misuse fell 50 percent in seven years, partly due to supply: An FDA-commissioned review (Journal of Clinical Psychopharmacology, June 2026) found misuse among adults under 30 dropped from 7.5% in 2016 to 3.7% in 2023, linked in part to the 2022 Adderall shortage.
- Evidence for non-medication ADHD approaches is first-line, not alternative: CBT, organizational skills training, and twice-weekly exercise each show strong evidence for improving executive function in children with ADHD—recommendations that were always in the guidelines, and rarely in the telehealth model.
What to Ask About Your Child’s ADHD Care
The industry shift is a market signal, not a verdict on any individual child’s treatment. Medication helps some children create the window of calm attention that makes skill-building possible. The question is whether the skill-building is actually happening inside that window.
If your child receives ADHD care primarily or exclusively through a telehealth provider, now is a useful time to ask what comes alongside any prescription. What behavioral support is built into the plan? Who is teaching your child to organize, plan, prioritize, and self-monitor? What is the provider’s answer if the current approach plateaus? A provider with no clear response to those questions is delivering an incomplete model—regardless of whether their prescribing practices are legal.
The enforcement wave is forcing ADHD telehealth to build what it should have included from the start. For parents, the useful move is to evaluate the full picture of what your child is currently getting and what skills they are actively building—not to panic about the enforcement, but to let it prompt the right questions.
Your child’s ability to strengthen focus, plan, and build executive function is real—and it grows with targeted practice. The obstacle was never a lack of evidence for that. It was a care model that treated the prescription as the destination and had no room left over for the skill-building the evidence demanded. That model is cracking. What replaces it is closer to what actually moves outcomes.
If you want a clear picture of which processing systems are making attention and learning harder for your child—and a roadmap built around building those skills, not just labeling the gap—start with a free AI assessment at Learning Success All Access.
See what All Access gives your child
Explore Focus Foundations
Is your child struggling in school?
Get your free personalized learning roadmap
You describe what you see at home. We turn it into a plan you start this week.
- Answer 5 short questionnaires about what you already notice, 30–45 minutes at your own kitchen table
- Your child sits no test and gets no score: nothing to schedule, nothing for them to dread
- You do the answering, the AI does the writing, and a person reviews it before it reaches you
- Access all 40+ courses instantly: reading, math, focus, processing and more, with new ones added regularly
Why we use AI, plainly: it writes from a knowledge base our team maintains and audits. We work through it line by line and pull anything the evidence stops supporting. The roadmap you get on Tuesday reflects what we corrected on Monday, and a human still reads it before you do.
Your school district must evaluate your child free of charge if you ask in writing, whatever your income and whatever the outcome (US, 34 CFR 300.111 and 300.301(b)). That route takes time and answers a different question than you do. This one starts today, from what you already know.
Your answers stay yours. We do not sell your personal information, and we do not hand identifiable assessment data to outside AI companies to train their models.
A screener is a starting point, not a diagnosis. If your child might need formal accommodations (an IEP or 504 plan), or you suspect a vision, hearing or medical cause, pursue a professional evaluation too. That is the only route to those supports.
References
- Behavioral Health Business — Virtual ADHD Providers Pivot Toward Coaching, Therapy Following Prescription Scrutiny
- Journal of Clinical Psychopharmacology (June 2026) via Psychiatry Advisor — Adult ADHD Stimulants Misuse Declines but Remains a Public Health Concern
- USC Keck School of Medicine — ADHD Medication Misuse Declines Among U.S. Adults, Study Finds
- HHS / DEA — DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Into 2026
- Neuronavigation — Beyond the Pill: Systematic Review of Executive Function Intervention Programs
